Duchenne Muscular Dystrophy (DMD)

Rare Disease·MeSH: Muscular Dystrophy, Duchenne

Prevalence

6.0 / 100K

Incidence

1.5 / 100K/yr

24 drugs in development·14 companies·7 clinical trials

Drug Pipeline by Phase

Approved(7)

Drug	Company
agamree	CATALYST PHARMACEUTICALS, INC. (CPRX)
AGAMREE®	CATALYST PHARMACEUTICALS, INC. (CPRX)
amondys 45	Sarepta Therapeutics, Inc. (SRPT)
deflazacort	Amneal Pharmaceuticals, Inc. (AMRX)
Emflaza	PTC THERAPEUTICS, INC. (PTCT)
exondys 51	Sarepta Therapeutics, Inc. (SRPT)
vyondys 53	Sarepta Therapeutics, Inc. (SRPT)

Phase 3(5)

Drug	Company
duchenne muscular dystrophy"	CAPRICOR THERAPEUTICS, INC. (CAPR)
edsp	Quince Therapeutics, Inc. (QNCX)
zeleciment basivarsen (z-basivarsen)	Dyne Therapeutics, Inc. (DYN)
zeleciment rostudirsen	Dyne Therapeutics, Inc. (DYN)
zeleciment rostudirsen (z-rostudirsen)	Dyne Therapeutics, Inc. (DYN)

Phase 2(2)

Drug	Company
Dyscorban®	CUMBERLAND PHARMACEUTICALS INC (CPIX)
iv infusion	PepGen Inc. (PEPG)

Phase 1(3)

Drug	Company
KER-065	Keros Therapeutics, Inc. (KROS)
PLN-101325	PLIANT THERAPEUTICS, INC. (PLRX)
rinvatercept	Keros Therapeutics, Inc. (KROS)

Early Phase 1(1)

Drug	Company
sat-3247	Satellos Bioscience Inc. (MSLE)

Phase 1/Phase 2(6)

Drug	Company
bmn 351	BIOMARIN PHARMACEUTICAL INC (BMRN)
entr-601-44	Entrada Therapeutics, Inc. (TRDA)
entr-601-45	Entrada Therapeutics, Inc. (TRDA)
entr-601-50	Entrada Therapeutics, Inc. (TRDA)
entr-601-51	Entrada Therapeutics, Inc. (TRDA)
entr-801	Entrada Therapeutics, Inc. (TRDA)

BioSniper tracks 24 drugs in development for Duchenne Muscular Dystrophy (DMD) across 14 companies.

There are 7 clinical trials targeting Duchenne Muscular Dystrophy (DMD) tracked by BioSniper.

The estimated prevalence of Duchenne Muscular Dystrophy (DMD) is approximately 6.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.